# To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers

> **NCT03543137** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 37 (actual)

## Conditions studied

- Tobacco Use Disorder

## Interventions

- **DRUG:** Nicotine Prototype Mini lozenge
- **DRUG:** Nicorette Mini Lozenge

## Key facts

- **NCT ID:** NCT03543137
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-18
- **Primary completion:** 2018-11-12
- **Final completion:** 2018-11-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03543137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03543137, "To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03543137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*